Overcoming Vemurafenib Resistance in Metastatic Melanoma: Targeting Integrins to Improve Treatment Efficacy
View/ Open
ijms-25-07946(1).pdf (4.863Mb)
Download
Publication date
2024-07-20Rights
© 2024 The Authors. This is an Open Access article distributed under the Creative Commons CC-BY license (https:// creativecommons.org/licenses/by/ 4.0/)Peer-Reviewed
YesOpen Access status
openAccess
Metadata
Show full item recordAbstract
Metastatic melanoma, a deadly form of skin cancer, often develops resistance to the BRAF inhibitor drug vemurafenib, highlighting the need for understanding the underlying mechanisms of resistance and exploring potential therapeutic strategies targeting integrins and TGF-β signalling. In this study, the role of integrins and TGF-β signalling in vemurafenib resistance in melanoma was investigated, and the potential of combining vemurafenib with cilengitide as a therapeutic strategy was investigated. In this study, it was found that the transcription of PAI1 and p21 was induced by acquired vemurafenib resistance, and ITGA5 levels were increased as a result of this resistance. The transcription of ITGA5 was mediated by the TGF-β pathway in the development of vemurafenib resistance. A synergistic effect on the proliferation of vemurafenib-resistant melanoma cells was observed with the combination therapy of vemurafenib and cilengitide. Additionally, this combination therapy significantly decreased invasion and colony formation in these resistant cells. In conclusion, it is suggested that targeting integrins and TGF-β signalling, specifically ITGA5, ITGB3, PAI1, and p21, may offer promising approaches to overcoming vemurafenib resistance, thereby improving outcomes for metastatic melanoma patients.Version
Published versionCitation
Boz Er AB, Sheldrake H and Sutherland M (2024) Overcoming Vemurafenib Resistance in Metastatic Melanoma: Targeting Integrins to Improve Treatment Efficacy. International Journal of Molecular Science. 25(14): 7946.Link to Version of Record
https://doi.org/10.3390/ijms25147946Type
Articleae974a485f413a2113503eed53cd6c53
https://doi.org/10.3390/ijms25147946